AZ, Daiichi's Enhertu cleared by FDA in wide range of tumors
Apr 8, 2024 · The latest nod marks Enhertu’s fifth approved indication in the U.S. The ADC, which won its original nod in 2019, is also cleared to treat HER2-positive and HER2-low breast cancer, plus gastric...
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
May 3, 2024 · The drug trastuzumab deruxtecan (Enhertu) can now be used to treat a wide variety of cancers, thanks to a new approval from the Food and Drug Administration (FDA).
Enhertu demonstrated a median progression-free survival ...
Jun 2, 2024 · With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
Enhertu demonstrated clinically meaningful survival across ...
Oct 23, 2023 · AstraZeneca and Daiichi Sankyo’s Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
Oct 19, 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
Enhertu achieved statistically significant overall survival ...
Dec 7, 2022 · Enhertu showed significant progression-free and overall survival improvements vs. chemotherapy in later-line HER2-positive setting in the DESTINY-Breast02 Phase III trial
ENHERTU ® Granted Two Breakthrough Therapy ... - Business Wire
Aug 31, 2023 · Designations for Daiichi Sankyo and AstraZeneca's ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colorectal cancer. ENHERTU has now been...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved ...
Apr 5, 2024 · AstraZeneca and Daiichi Sankyo's ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
FDA approves new treatment option for patients with HER2 ...
FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more...
Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer
Jul 5, 2022 · Enhertu extended survival in patients with metastatic HER2-low breast cancer longer than standard chemo, a clinical trial showed.